Maxim Group analyst Naz Rahman has reiterated their bullish stance on NVCT stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Naz Rahman has given his Buy rating due to a combination of factors, primarily focusing on the promising clinical potential of Nuvectis Pharma’s lead asset, NXP900. The recent positive results from the Drug-Drug Interaction study highlight NXP900’s potential as a combination therapy with EGFR and ALK inhibitors, which are crucial for treating non-small cell lung cancer (NSCLC) patients who have developed resistance to these inhibitors.
NXP900’s ability to act as a weak inducer of CYP3A without causing serious adverse effects further supports its development as a combination therapy. The study’s findings suggest that NXP900 can be safely co-administered with EGFR and ALK inhibitors, potentially enhancing their efficacy and tolerability. Given the large market for lung cancer treatments and the limited options for patients with resistant tumors, NXP900’s development pathway appears promising, justifying the Buy rating.
Rahman covers the Healthcare sector, focusing on stocks such as Kazia Therapeutics, Aytu BioScience, and Nuvectis Pharma. According to TipRanks, Rahman has an average return of -19.0% and a 28.00% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.